Pharmaceutical Technology9h
Novo Nordisk plans new study for CagriSema, targets 2026 submission
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
The Obesity Market Is Growing Just Fine. But Investors Want to Know What’s Next
Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...
FiercePharma15h
Nephrologists already aboard GLP-1 bandwagon, providing launchpad for Ozempic in CKD: Spherix
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
Ozempic Could Get Way Too Expensive Under Trump—Here's What You Can Do
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.
JPMorgan cuts Novo Nordisk target, keeps Overweight rating
JPMorgan analysts revised their outlook on Novo Nordisk (NYSE:NVO) stock, reducing the price target to DKK1,000 from DKK1,050. Despite the adjustment, they maintained an Overweight rating on the ...
GSK tells Labour to back British firms after Astra bust-up
Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...
Novo Nordisk Outlook Provides Some Welcome Relief
The company's shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...